About this trial
This is a single-center single-arm study. The main purpose of this study is to study the efficacy of surgical treatment for patients with locally advanced cervical cancer (FIGO IB3, IIA2-IVA) who still have residual tumor after concurrent radiotherapy and chemotherapy.
Eligibility criteria
Qualifiers
Stage Ib3 and IIA2-IVA (FIGO2018) cervical cancer with histopathology of squamous cell carcinoma, adenosquamous cell carcinoma, adenocarcinoma.
Complete standard CCRT(Pelvic EBRT+ concurrent platinum-containing chemotherapy+ brachytherapy).
After 4-12 weeks of treatment, the cervical biopsy pathology confirmed residual cancer, or the cervical biopsy was negative, but PET /CT showed that SUVmax of the residual lesions in the cervical and/or pelvic lymph nodes were ≥ 2.5, two or more gynaecological oncologists with Grade IV operation qualification and the title of deputy director or above have gynecological examination, and the multidisciplinary team(MDT) evaluation recommended surgical treatment.
ECOG score:0 ~ 1.
Disqualifiers
The radiotherapy and chemotherapy are not completed or the radiotherapy dose is not reached.
PET /CT and/or pathological indicates that there is a distant metastasis including para-aortic lymph nodes.
Other malignancies were diagnosed within five years or needed treatments.
History of important organ transplantation.
Trial design
Treatments tested in this trial
- salvage surgery